Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma

@article{Iribarren2017CardiovascularAC,
  title={Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma},
  author={Carlos Iribarren and Abdelkader Rahmaoui and Aidan A. Long and Stanley J. Szefler and Mary S. Bradley and Gillis Carrigan and Mark D. Eisner and Hubert C. Chen and Theodore A. Omachi and Michael E Farkouh and Kenneth J. Rothman},
  journal={The Journal of Allergy and Clinical Immunology},
  year={2017},
  volume={139},
  pages={1489–1495.e5}
}

Figures and Tables from this paper

Tolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up

Compliance with omalizumab mildly decreased over 10 years but was not affected by severe adverse events of treatment or new comorbidities.

Omalizumab as a Provoking Factor for Venous Thromboembolism

Omalizumab has been associated with arterial and venous thromboembolic events, although the evidence is not definitive, and the EXCELS study, a postmarketing observational cohort study to assess clinical safety profile of omalizuab, showed a significant increase in venousThrombo embolism.

Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Reduced longitudinal cardiac strain in asthma patients

Allergic asthma, especially severe asthma is associated with subclinical impaired left and right ventricular function as determined by speckle-tracking analysis.

Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system

The safety profile of biologicals used in asthma, especially in the most severe forms of the disease, is characterized by retrospective and descriptive analysis of spontaneous reports sent to the Portuguese Pharmacovigilance System since market launch.

Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life

This study, the longest clinical follow-up on patients treated with anti-IgE, confirms and amplifies the results of the studies carried out so far, as they are maintained over a very long interval of time without drops in efficacy without any type of side effect.

Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria

The neutrophils, lymphocytes, platelet counts, NLR, PLR, MPV, and PDW before, during, and after omalizumab treatment and compared the results with those of healthy controls were analyzed.

Omalizumab induced Takotsubo syndrome: case report

This is the first case of Takotsubo syndrome following the administration of omalizumab, a humanized monoclonal anti-immunoglobulin E antibody approved for the treatment of spontaneous chronic urticaria, with high efficacy and an excellent safety profile.
...

References

SHOWING 1-10 OF 45 REFERENCES

Baseline characteristics of patients enrolled in EXCELS: a cohort study.

  • A. LongJ. Fish S. Szefler
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2009

Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.

Longitudinal Changes in Asthma Control with Omalizumab: 2-Year Interim Data from the EXCELS Study

Over a 2-year period, patients initiating omalizumab therapy experienced clinically relevant improvements in asthma control, which were maintained during 2 years of longitudinal follow-up.

Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis.

In this large multiethnic cohort of individuals free of known CVD at its inception, persistent asthmatics had a higher CVD event rate than nonasthmatics.

Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica.

In patients with PMR, treatment with glucocorticoids is not associated with an increased risk of cardiovascular diseases, and a trend for a protective effect was seen.

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.

Abstract 15991: Chronic Asthma Predicts Cardiovascular Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA)

In this large multi-ethnic cohort, asthmatics on CM had a higher CVD event rate compared to non-asthmatics, and increased CVD risk among astHmatics may be related to increased inflammatory stress.

Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study.

GCs are associated with an increased risk of MI in RA, an immediate effect mediated through current dosage and a long-term effect of cumulative exposure, which is suggested to be a dual effect.